Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
134
Views
2
CrossRef citations to date
0
Altmetric
CASE REPORT

Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker

Yixin Kang1 Department of Respiratory Diseases, the First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of ChinaView further author information
,
Cheng Ge2 Department of Cardiology, the First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of ChinaView further author information
,
Huan Zhang3 Center of Medicine Clinical Research, the First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of ChinaView further author information
,
Saizhe Liu4 Department of Cardiology, the Sixth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of ChinaView further author information
,
Hongyang Guo4 Department of Cardiology, the Sixth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
&
Junchang Cui1 Department of Respiratory Diseases, the First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, 100853, People’s Republic of ChinaView further author information
Pages 4467-4470 | Published online: 12 Aug 2022

References

  • Hoy SM. Contezolid: first Approval. Drugs. 2021;81:1587–1591. doi:10.1007/s40265-021-01576-0
  • Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014;57:4487–4497. doi:10.1021/jm401931e
  • Shoen C, DeStefano M, Hafkin B, et al. In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018;1:62.
  • Erturan Z, Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents. 2005;26:78–80. doi:10.1016/j.ijantimicag.2005.03.006
  • Maltempe FG, Caleffi-Ferracioli KR, Do Amaral RCR, et al. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis. Tuberculosis. 2017;104:24–29. doi:10.1016/j.tube.2017.02.004
  • Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508–1518. doi:10.1056/NEJMoa1201964
  • Vinha DC, Rubinstein E. Linezolid: a review of safety and tolerability. Journal of Infection. 2009;59:S59–S74. doi:10.1016/S0163-4453(09)60009-8
  • Junping L, Ramesh CT, Tripathi BJ. Drug-Induced Ocular Disorders. Drug Safety. 2008;31:127–141. doi:10.2165/00002018-200831020-00003
  • Wright A, Deane-Alder K, Marschall E, et al. Characterization of the Core Ribosomal Binding Region for the Oxazolidone Family of Antibiotics Using Cryo-EM. ACS Pharmacol Transl Sci. 2020;3:425–432. doi:10.1021/acsptsci.0c00041

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.